nmCRPC COE

ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans

Details
Zach Klaassen and Alicia Morgans discuss the findings from an exploratory analysis of the ARAMIS trial, focusing on the efficacy of darolutamide for non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Morgans explains that darolutamide, approved after the ARAMIS phase 3 trial, significantly improves metastasis-free survival by 22 months and reduces mortality by 31% compared to placeb...

Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era - Neal Shore

Details
Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. Dr. Shore reflects on three pivotal trials—SPARTAN, PROSPER, and ARAMIS—that have redefined treatment approaches by demonstrating the efficacy of apalutamide, enzalutamide, and dar...

Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger

Details
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in clinical settings, attributing this shift to advanced imaging techniques, especially PSMA PET scans, which more accurately detect metastatic stages. He notes that in 2022 and 2023, only about 8% of ne...

The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian

Details
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...

Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone

Details
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...

Trends in Prostate Cancer Diagnosis in Transgender Women - Farnoosh Nik-Ahd

Details
In this conversation, Alicia Morgans and Farnoosh Nik-Ahd discuss the diagnosis of prostate cancer in transgender women. Dr. Nik-Ahd highlights that despite gender affirmation surgeries, transgender women, who were assigned male at birth, retain their prostates and therefore remain at risk for prostate cancer. Using data collected from the Veterans Health Administration, she discusses the complexi...

223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...

Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan

Details
Alicia Morgans is joined by Drs Fred Saad, Charles Ryan, and Tomasz Beer at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland, to discuss holistic treatment of men with prostate cancer who are being treated with ADT. Dr. Ryan discusses the lack of data on the treatment of depression in men on hormone therapy. Dr. Saad discusses the need to be aware of the patien...

Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen

Details
Zach Klaassen joins Alicia Morgans in discussing an underestimated topic of mental health and its effects on patients with genitourinary cancers. Drs. Klaassen and Morgans discuss hypothesis-generating population-level data in this landscape and talk through the importance of supporting these patients and using what Dr. Klaassen refers to as clinical intuition and asking follow-up questions when s...

Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke

Details
Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic castrati...